Investors are looking more favorably at diagnostics than they have in years—driven in part by major success stories despite tumultuous public and private markets. In the public markets, Gen-Probe Inc. , and Roche 's Igen International Inc. are stand-out examples of diagnostics' ability to deliver stellar returns. (See "Roche Pays $1.4 billion for Igen and Gets Peace of Mind," IN VIVO, September 2003 Also see "Roche Pays $1.4 Billion for Igen and Gets Peace of Mind" - In Vivo, 1 September, 2003..)
Still, anyone looking at the field would do well to consider the cautionary, still-evolving tale of Cepheid as an indication of the complexities inherent in building a new diagnostic enterprise. Cepheid has more going for it than most diagnostic start-ups. For starters, its CEO and president, John Bishop, has a track record of success in building diagnostic businesses. The firm recently won a lucrative, steady biodefense contract from the United States Postal Service (USPS) as part of a consortium led by Northrup Grumman, and, in March, it introduced its first clinical diagnostic assay
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?